-
XtalPi Partners with CTTQ for AI-Driven Small-Molecule Drug Development
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177). The two will work together on the development of small-molecule drugs in the liver disease field. No financial details were disclosed. AI…
-
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
•
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands, and Suzhou (China), announced the conclusion of a Phase I clinical study for its anti-CTLA-4 antibody HBM4003 combined with Junshi Bio’s programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) in advanced melanoma. The study has shown that…
-
Frontier Biotechnologies Partners with Yuyue Med for FB2001 Atomizer
•
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223). Yuyue Med will supply Frontier Bio the atomizer of the designated model used in the early clinical trials of the FB2001 atomized inhalant bofutrelvir at a discounted price, alongside…
-
Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech
•
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio’s proprietary All H2L2 transgenic Harbour Mice platform…
-
ExoNeuglia Secures Angel Funding for iPSC-Based Cell Therapy
•
ExoNeuglia, a stem-cell-focused biotech based in Suzhou, reportedly raised “tens of millions” of renminbi in an angel financing round, solely backed by RedHill Capital. The company is self-described as the first domestic cell therapy company utilizing induced pluripotent stem cells (iPSCs) technology to treat demyelinating diseases. Demyelinating Diseases and Treatment…
-
Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation
•
The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s (HKG: 1167) KRAS G12C inhibitor JAB-21822 has received breakthrough therapy designation (BTD) status for its potential as a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS p.G12C mutation. The…
-
CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials
•
China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both announced receiving the green light from the National Medical Products Administration (NMPA) to carry out clinical trials for their respective SYH2055 and ASC11, both inhibitor drugs targeting 3-chymotrypsin like protease (3CLpro) for COVID-19. Market Landscape…
-
24 Provinces Form Alliances for Volume-Based Procurement of Medical Consumables
•
The Henan provincial alliance procurement office released a notification indicating that 24 provinces/regions will form three provincial alliances to carry out volume-based procurement (VBP) of six categories of medical consumables, covering hemodialysis, neurosurgery, neural intervention, peripheral intervention, general intervention, and cochlear implants. The participating regions include Henan, Hebei, Shanxi, Inner…
